- Report
- October 2025
- 187 Pages
Global
From €3145EUR$3,545USD£2,730GBP
€3494EUR$3,939USD£3,034GBP
- Report
- October 2025
- 199 Pages
Global
From €3145EUR$3,545USD£2,730GBP
€3494EUR$3,939USD£3,034GBP
- Report
- October 2025
- 196 Pages
Global
From €3145EUR$3,545USD£2,730GBP
€3494EUR$3,939USD£3,034GBP
- Report
- October 2025
- 184 Pages
Global
From €3145EUR$3,545USD£2,730GBP
€3494EUR$3,939USD£3,034GBP
- Report
- October 2025
- 186 Pages
Global
From €3145EUR$3,545USD£2,730GBP
€3494EUR$3,939USD£3,034GBP
- Report
- October 2025
- 194 Pages
Global
From €3145EUR$3,545USD£2,730GBP
€3494EUR$3,939USD£3,034GBP
- Report
- October 2025
- 185 Pages
Global
From €3145EUR$3,545USD£2,730GBP
€3494EUR$3,939USD£3,034GBP
- Report
- August 2025
- 186 Pages
Global
From €3145EUR$3,545USD£2,730GBP
€3494EUR$3,939USD£3,034GBP
- Report
- August 2025
- 180 Pages
Global
From €3145EUR$3,545USD£2,730GBP
€3494EUR$3,939USD£3,034GBP
- Report
- August 2025
- 190 Pages
Global
From €3145EUR$3,545USD£2,730GBP
€3494EUR$3,939USD£3,034GBP
- Report
- October 2025
- 459 Pages
Global
From €5189EUR$5,850USD£4,505GBP
- Report
- October 2025
- 582 Pages
Global
From €5189EUR$5,850USD£4,505GBP
- Report
- October 2025
- 270 Pages
Global
From €5189EUR$5,850USD£4,505GBP
- Report
- October 2025
- 620 Pages
Global
From €5189EUR$5,850USD£4,505GBP
- Report
- October 2025
- 250 Pages
Global
From €3983EUR$4,490USD£3,458GBP
- Report
- September 2025
- 250 Pages
Global
From €3983EUR$4,490USD£3,458GBP
- Report
- September 2025
- 250 Pages
Global
From €3983EUR$4,490USD£3,458GBP
- Report
- September 2025
- 250 Pages
Global
From €3983EUR$4,490USD£3,458GBP
- Report
- September 2025
- 250 Pages
Global
From €3983EUR$4,490USD£3,458GBP
- Report
- April 2025
- 175 Pages
Global
From €3983EUR$4,490USD£3,458GBP

The Soft Mist Inhaler (SMI) is a type of inhaler used to deliver medication to the lungs. It is a breath-activated device that produces a fine mist of medication, which is then inhaled by the patient. SMIs are used to treat a variety of respiratory conditions, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. They are also used to deliver medications for other conditions, such as allergies and COPD.
SMIs are becoming increasingly popular due to their convenience and ease of use. They are also more cost-effective than other inhalers and nebulisers, making them a viable option for many patients. SMIs are also more discreet than other inhalers, making them a preferred choice for those who need to take their medication in public.
The SMI market is highly competitive, with a number of companies offering a range of products. These include GlaxoSmithKline, Boehringer Ingelheim, Novartis, Merck, and AstraZeneca. Other companies in the market include 3M, Philips, and Teva Pharmaceuticals. Show Less Read more